High-Tech in Hospitals
Medical high-tech interventions are often applied for their first time in hospitals. The maintenance of the benefit catalogue, i.e. decision support for the in-/exclusion of new techniques or innovative treatments, is based on evidence analyses of individual interventions (surgical procedures, new techniques and implants, diagnostic methods) for - mostly clearly defined indications and patient groups.
The LBI-HTA has a particular focus on the maintenance of the Austrian hospital service catalogue (called MEL / individual medical services) within the scope of the DRG- compensation.
Head of department: Claudia Wild
Public Health and Health Services Research
The evaluation of complex interventions, i.e. interventions that are provided by different providers in different organizational settings, is gaining importance in the maintenance of benefit catalogues as well as in the measurement and – comparison of outcomes. Evidence-based health services research is a relatively young discipline that is committed – as evidence-based medicine - to the instruments of systematic searches and analyses, transparent presentation of the sources and methods of analysis, but also to interdisciplinary perspectives.
The LBI-HTA has a particular focus on the assessment of rehabilitation and occupational therapies as well as psychological / psychiatric interventions.
Head of department: Brigitte Piso
Drugs that have been approved by the European Medicines Agency (EMA) are being introduced simultaneously, medical devices and other medical technologies nearly simultaneously to all European markets. International, especially European coordination of HTA-activities and collaboration is therefore of increasing importance to avoid redundancies and duplication of efforts in the assessment of medical technologies prior to reimbursement and coverage decision.
EUnetHTA (European Network for Health Technology Assessment) and AdHopHTA (Adopting HTA in hospitals) are working on the intensification of structures and networks for cross-border HTA cooperation.
Another focus of the LBI-HTA is the cooperation in the assessment of new oncology drugs, but also of devices and other medical interventions.
Head of department: interim: Claudia Wild